Autonomix medical, inc. finalizes design of asic microchip for sensing technology catheter for use in humans, continuing progress toward a u.s. pivotal trial in 2025

Design lock for asic microchip follows successful completion of in vivo preclinical and extensive bench testing manufacturing of asic microchip for targeted use in humans has been initiated company advancing toward submitting investigational device exemption (“ide”), and if approved, will commence a pivotal clinical trial to support a de novo application for fda approval the woodlands, tx, jan. 17, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has finalized the design, achieving “design lock”, for its application specific integrated circuits (asic) microchip following the successful completion of in vivo preclinical testing and extensive bench testing, continuing progress toward its u.s. pivotal trial. “this design lock represents a significant milestone in the advancement of our innovative technology, placing us another step closer to commencing a pivotal clinical trial in the united states, planned in 2025.
AMIX Ratings Summary
AMIX Quant Ranking